Euroasian Journal of Hepato-Gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 6 , ISSUE 1 ( January-June, 2016 ) > List of Articles

MINI REVIEW

Past, Present, and Future of Viral Hepatitis C in Japan

Hiroshi Yatsuhashi

Citation Information : Yatsuhashi H. Past, Present, and Future of Viral Hepatitis C in Japan. Euroasian J Hepatogastroenterol 2016; 6 (1):49-51.

DOI: 10.5005/jp-journals-10018-1166

License: CC BY-NC 4.0

Published Online: 01-01-2016

Copyright Statement:  Copyright © 2016; The Author(s).


Abstract

Of all the industrialized countries of the world, Japan has the highest rate of hepatitis C. It also has 1 of the oldest and most varied histories of hepatitis C in the world among the industrialized modern nations. Hepatitis C and its complications are the leading cause of liver cancer in Japan. Japan has the highest rate of liver cancer among the industrialized countries. From 2004 to 2014, PegIFN/RBV treatment was the mainstream of hepatitis C treatment. In 2014, the first interferon-free therapy was approved in Japan. Subsequently, other interferon-free therapies have been approved. Hepatitis C virus disinfection in hepatitis C patients in Japan has become possible with a probability of 96% or more.

PDF Share
  1. Franciscus A. HCV Around the World: Japan. HCV Advocate 2015. Available from: http://www.hcvadvocate.org/ 2. Blaxell V. Yellow blood: hepatitis C and the modernist settlement in Japan. Asia-Pacific J 2014 May 5;12(18 No 1):1-18
  2. Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatolol 2005 Jan;42(1):47-53
  3. Methamphetamine use in Japan after the Second World War: transformation of narratives. Contemp Drug Probl 2008 Dec;35(4):717-746
  4. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 Jun;59(6):2083-2089
  5. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014 Nov;21(11):762-768
  6. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015 Jun;15(6):645-653.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.

We use cookies on this site to enhance your user experience.

By clicking any link on this page you are giving your consent for us to set cookies.